Literature DB >> 25765968

Plasmodium vivax gametocyte proteins, Pvs48/45 and Pvs47, induce transmission-reducing antibodies by DNA immunization.

Mayumi Tachibana1, Nantavadee Suwanabun2, Osamu Kaneko3, Hideyuki Iriko4, Hitoshi Otsuki5, Jetsumon Sattabongkot2, Akira Kaneko6, Socrates Herrera7, Motomi Torii8, Takafumi Tsuboi9.   

Abstract

Malaria transmission-blocking vaccines (TBV) aim to interfere with the development of the malaria parasite in the mosquito vector, and thus prevent spread of transmission in a community. To date three TBV candidates have been identified in Plasmodium vivax; namely, the gametocyte/gamete protein Pvs230, and the ookinete surface proteins Pvs25 and Pvs28. The Plasmodium falciparum gametocyte/gamete stage proteins Pfs48/45 and Pfs47 have been studied as TBV candidates, and Pfs48/45 shown to induce transmission-blocking antibodies, but the candidacy of their orthologs in P. vivax, Pvs48/45 (PVX_083235) and Pvs47 (PVX_083240), for vivax TBV have not been tested. Herein we investigated whether targeting Pvs48/45 and Pvs47 can inhibit parasite transmission to mosquitoes, using P. vivax isolates obtained in Thailand. Mouse antisera directed against the products from plasmids expressing Pvs48/45 and Pvs47 detected proteins of approximately 45- and 40-kDa, respectively, in the P. vivax gametocyte lysate, by Western blot analysis under non-reducing conditions. In immunofluorescence assays Pvs48/45 was detected predominantly on the surface and Pvs47 was detected in the cytoplasm of gametocytes. Membrane feeding transmission assays demonstrated that anti-Pvs48/45 and -Pvs47 mouse sera significantly reduced the number of P. vivax oocysts developing in the mosquito midgut. Limited amino acid polymorphism of these proteins was observed among 27 P. vivax isolates obtained from Thailand, Vanuatu, and Colombia; suggesting that polymorphism may not be an impediment for the utilization of Pvs48/45 and Pvs47 as TBV antigens. In one Thai isolate we found that the fourth cysteine residue in the Pvs47 cysteine-rich domain (CRD) III (amino acid position 337) is substituted to phenylalanine. However, antibodies targeting Pvs47 CRDI-III showed a significant transmission-reducing activity against this isolate, suggesting that this substitution in Pvs47 was not critical for recognition by the generated antibodies. In conclusion, our results indicate that Pvs48/45 and Pvs47 are potential transmission-blocking vaccine candidates of P. vivax.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  DNA vaccine; Gametocyte; Malaria; Plasmodium vivax; Polymorphism; Transmission-blocking vaccine

Mesh:

Substances:

Year:  2015        PMID: 25765968     DOI: 10.1016/j.vaccine.2015.03.008

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  27 in total

Review 1.  Transmission-Blocking Vaccines: Old Friends and New Prospects.

Authors:  Festus K Acquah; Joshua Adjah; Kim C Williamson; Linda E Amoah
Journal:  Infect Immun       Date:  2019-05-21       Impact factor: 3.441

Review 2.  The s48/45 six-cysteine proteins: mediators of interaction throughout the Plasmodium life cycle.

Authors:  Silvia A Arredondo; Stefan H I Kappe
Journal:  Int J Parasitol       Date:  2016-11-27       Impact factor: 3.981

Review 3.  Plasmodium P47: a key gene for malaria transmission by mosquito vectors.

Authors:  Alvaro Molina-Cruz; Gaspar E Canepa; Carolina Barillas-Mury
Journal:  Curr Opin Microbiol       Date:  2017-12-08       Impact factor: 7.934

4.  Evaluation of Plasmodium vivax HAP2 as a transmission-blocking vaccine candidate.

Authors:  Yue Qiu; Yan Zhao; Fei Liu; Bo Ye; Zhenjun Zhao; Sataporn Thongpoon; Wanlapa Roobsoong; Jetsumon Sattabongkot; Liwang Cui; Qi Fan; Yaming Cao
Journal:  Vaccine       Date:  2020-02-21       Impact factor: 3.641

5.  Genetic diversity of transmission-blocking vaccine candidate Pvs48/45 in Plasmodium vivax populations in China.

Authors:  Hui Feng; Bhavna Gupta; Meilian Wang; Wenqi Zheng; Li Zheng; Xiaotong Zhu; Yimei Yang; Qiang Fang; Enjie Luo; Qi Fan; Takafumi Tsuboi; Yaming Cao; Liwang Cui
Journal:  Parasit Vectors       Date:  2015-12-01       Impact factor: 3.876

6.  Immunological Cross-Reactivity between Malaria Vaccine Target Antigen P48/45 in Plasmodium vivax and P. falciparum and Cross-Boosting of Immune Responses.

Authors:  Yi Cao; Geetha P Bansal; Kristen Merino; Nirbhay Kumar
Journal:  PLoS One       Date:  2016-07-20       Impact factor: 3.240

7.  Global genetic diversity of the Plasmodium vivax transmission-blocking vaccine candidate Pvs48/45.

Authors:  Andres F Vallejo; Nora L Martinez; Alejandra Tobon; Jackeline Alger; Marcus V Lacerda; Andrey V Kajava; Myriam Arévalo-Herrera; Sócrates Herrera
Journal:  Malar J       Date:  2016-04-12       Impact factor: 2.979

8.  Characterization of a Plasmodium berghei sexual stage antigen PbPH as a new candidate for malaria transmission-blocking vaccine.

Authors:  Xu Kou; Wenqi Zheng; Feng Du; Fei Liu; Meilian Wang; Qi Fan; Liwang Cui; Enjie Luo; Yaming Cao
Journal:  Parasit Vectors       Date:  2016-04-02       Impact factor: 3.876

9.  Effects of transmission-blocking vaccines simultaneously targeting pre- and post-fertilization antigens in the rodent malaria parasite Plasmodium yoelii.

Authors:  Li Zheng; Wei Pang; Zanmei Qi; Enjie Luo; Liwang Cui; Yaming Cao
Journal:  Parasit Vectors       Date:  2016-08-08       Impact factor: 3.876

10.  Characterization of Pv92, a Novel Merozoite Surface Protein of Plasmodium vivax.

Authors:  Seong-Kyun Lee; Bo Wang; Jin-Hee Han; Myat Htut Nyunt; Fauzi Muh; Patchanee Chootong; Kwon-Soo Ha; Won Sun Park; Seok-Ho Hong; Jeong-Hyun Park; Eun-Taek Han
Journal:  Korean J Parasitol       Date:  2016-08-31       Impact factor: 1.341

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.